

Review Article

The Inflammatory Chemokine CCL5 and Cancer Progression

Donatella Aldinucci¹ and Alfonso Colombatti^{1,2}

¹ *Experimental Oncology 2, Aviano National Cancer Institute (CRO), Via Franco Gallini 2, 33081 Aviano, Italy*

² *Department of Medical and Biological Science Technology, Microgravity Ageing Training Immobility Excellence Center (MATI), Piazzale M. Kolbe, 33100 Udine, Italy*

Correspondence should be addressed to Donatella Aldinucci; daldinucci@cro.it

Received 10 September 2013; Accepted 10 December 2013; Published 2 January 2014

Academic Editor: Mohammad Athar

Copyright © 2014 D. Aldinucci and A. Colombatti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Until recently, inflammatory chemokines were viewed mainly as indispensable “gate keepers” of immunity and inflammation. However, updated research indicates that cancer cells subvert the normal chemokine system and these molecules and their receptors become important constituents of the tumor microenvironment with very different ways to exert tumor-promoting roles. The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. This review summarizes updated information on the role of CCL5 and its receptor CCR5 in cancer cell proliferation, metastasis, and the formation of an immunosuppressive microenvironment and highlights the development of newer therapeutic strategies aimed to inhibit the binding of CCL5 to CCR5, to inhibit CCL5 secretion, or to inhibit the interactions among tumor cells and the microenvironment leading to CCL5 secretion.

1. Introduction

Epidemiological and experimental studies provided clear evidence that unresolved pathogen infections and chronic inflammation promote tumor development and led to the inclusion of inflammation among the hallmarks of cancer [1, 2]. On the other hand, cancer cells not only make themselves “invisible” to the immune system, but also favor the formation of an immunosuppressive microenvironment unable to eliminate cancer cells [3]. As a result, the reduced secretion of molecules acting as tumor-promoting factors and the normalization of the tumor microenvironment [4] are main goals to develop appropriate antitumor strategies.

The tumor microenvironment is composed of stromal and inflammatory cells that are recruited and/or locally induced to proliferate or differentiate by tumor cells or by normal cells “educated” by tumor cells. They communicate directly through cell-cell contact but also indirectly through paracrine signals [4]. These signals are predominantly constituted by cytokines and chemokines (chemotactic cytokines), key orchestrators of leukocytes trafficking under homeostatic

conditions as well as during inflammation and cancer [5] and part of the molecular pathways driving cancer cell survival, motility, and invasiveness [6].

Chemokines, identified on the basis of their ability to induce chemotaxis, have a fundamental role not only in inflammation and immune surveillance but also in cancer progression [7]. Chemokines, secreted by the tumor cells from primary tumors or metastatic sites or by the normal cells recruited and/or locally activated, can behave as growth factors [8], increase metastasis formation and angiogenesis, [9] or induce the formation of an immunosuppressive microenvironment. This last complex capacity is obtained by recruiting activating tumor-associated macrophages (TAM) [10], myeloid-derived suppressor cells (MDSC), T-regulatory cells (T-reg) [11], or mesenchymal stem cells (MSCs) [12] and by inhibiting the antitumor activity of Th1 cells and cytotoxic T lymphocytes (CTL) [13].

In response to chemokines present in remote organs, tumor cells that express the corresponding receptor disseminate with higher efficiency [14]. Furthermore, tumor cells

acquire higher adhesive, migratory, and invasive properties in response to chemokines that are expressed at preferential metastatic sites [15]. As a consequence, the presence of inflammatory cells such as reactive leukocytes and the expression of a large number of inflammatory mediators (e.g., cytokines, chemokines, and enzymes) in the primary tumor are mostly associated with poor prognosis and metastasis formation [16].

A variety of chemokines and chemokine receptors have been detected in neoplastic tissues [1, 4]. We will focus our attention primarily on the C-C chemokine ligand 5 (CCL5), also known as Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES), and its receptors C-C chemokine receptor type 5 (CCR5).

CCR5 is a seven-transmembrane G-protein-coupled receptor, mediating diverse signaling cascades in response to its ligands. CCR5, a promiscuous receptor, binds with high-affinity CCL5, CCL3 (MIP-1a), and CCL4 (MIP-1b) and is the major coreceptor for HIV [17].

CCL5 belongs to the C-C chemokine family whose members also include CCL3 and CCL4 [18]. CCL5, a target gene of NF- κ B activity, is expressed by T lymphocytes, macrophages, platelets, synovial fibroblasts, tubular epithelium, and certain types of tumor cells [18]. NF- κ B activation by different stimuli such as CD40L [19] or IL-15 [20] induces CCL5 production.

CCL5 plays an active role in recruiting a variety of leukocytes into inflammatory sites including T cells, macrophages, eosinophils, and basophils. In collaboration with certain cytokines that are released by T cells such as IL-2 and IFN- γ , CCL5 also induces the activation and proliferation of particular natural killer cells to generate C-C chemokine-activated killer cells [18]. CCL5 produced by CD8⁺ T cells and other immune cells has been shown to inhibit HIV entry into target cells.

CCL5 activity is mediated through its binding to CCR1, CCR3, and mainly CCR5 [18]. CCR4 [21, 22] and CD44 are auxiliary receptors for CCL5 [21, 23].

The exact functions of CCL5 in tumor biology are still unclear. CCL5 production is relevant to inducing proper immune responses against tumors [2], but, on the other hand, CCL5 is associated with cancer progression and metastasis.

CCL5/CCR5 interactions may favor tumor development in multiple ways: acting as growth factors, stimulating angiogenesis, modulating the extracellular matrix, inducing the recruitment of additional stromal and inflammatory cells, and taking part in immune evasion mechanisms [3].

A schematic view of the consequences of the CCL5/CCR5 interactions in cancer is shown in Figure 1.

This review summarizes updated information on the role of the CCL5/CCR5 axis in tumor development and/or progression, focusing primarily on multiple myeloma (MM), classical Hodgkin lymphoma (cHL), prostate, breast, gastric, colon, and ovarian cancer, and melanoma.

Based on the findings obtained so far, we propose that inflammatory chemokines and their receptors are attractive therapeutic targets in malignancy.




FIGURE 1: Effects of the CCL5/CCR5 interactions in cancer. Cancer cells secrete CCL5 or induce fibroblasts to secrete CCL5 which act in a paracrine or autocrine fashion on CCR5-positive tumor cells to sustain their proliferation, to recruit immunosuppressive cells (T-reg cells, monocyte), to induce osteoclasts activation and bone metastasis, to induce neoangiogenesis, and to guide tumor cells to disseminate to distant organs.

2. Mechanism Leading to Cancer Cell Proliferation and Metastasis Formation via the CCL5/CCR5 Axis

The binding of chemokine to their G-protein-coupled receptors (GPCRs) activates a series of downstream effectors that facilitate internalization of the receptor and signal transduction leading to integrin activation (adhesion) and polarization of the actin cytoskeleton [24]. The consequences are directional sensing, cell polarization, accumulation of small GTPases, Rac, Cdc42, and PI3K at the leading edge, actin polymerization, and F-actin formation. These changes cause actomyosin contraction and tail retraction and finally cell migration [24].

More specifically, CCL5 contributes to the activation of the α v β 3 integrin and to cell migration through PI3K/Akt, which in turn activates IKK α /beta and NF- κ B [25]. NF- κ B activation also can elevate the secretion of MMP-9 [26] or promote invasion by increasing the secretion of both MMP-2 and -9 and by activating the ERK and Rac signaling [27]. CCL5 induces migration also by upregulating the activities of MMP-9 through STAT3 [28]. In other instances CCL5/CCR5 acts via MEK, ERK, and then NF- κ B, resulting in the activations of α v β 3 integrin and contributing to cell migration [29].

Chemokines, by activating the tyrosine kinase receptors, the Jak-STAT, or the MAPK/ERK signaling pathway, also promote tumor cell proliferation [30]. Exogenous CCL5 stimulates cell proliferation by inducing the mTOR pathway, leading to a rapid upregulation of cyclin D1, c-Myc, and Dad-1 expression. An additional mechanism based on the CCL5-CCR5 interaction can lead to increased cell proliferation:

increased glucose uptake, increased ATP production, and enhanced glycolysis, associated with extracellular acidification [31].

3. The CCL5/CCR5 Axis in Hematological Malignancies

Many studies were published during the last several years on the expression of CCL5 and CCR5 in hematological malignancies, but, only for multiple myeloma (MM) and at least in part for cHL, we have a comprehensive view of the role played by the CCL3-CCL5/CCR5 pair.

3.1. Multiple Myeloma. The MM cell localization in the bone marrow and the cross-talk with the bone niche trigger dramatic alterations in the bone marrow (BM) microenvironment, critical for tumor progression, resistance to therapies, and osteolytic bone destruction [32]. The interaction between osteoclasts (OCs) and MM cells plays a key role in the pathogenesis of MM-related osteolytic bone disease. MM cells promote OCs formation and, in turn, OCs enhance tumor cell proliferation via cell-cell contact [33].

The CCR5-ligand CCL3 is detected in MM cell line and freshly isolated MM cells [34, 35] and is one of the most important OC-activating factors produced by MM cells and a contributor of MM-associated osteolytic bone disease [36]. MM cells from patients with multiple bone lesions secrete higher amounts of CCL3 (and CCL4) than those with less-advanced bone involvement [37]. Consistently, CCL3 serum levels are elevated in newly diagnosed MM patients and correlate with the extent of bone disease, bone resorption, and disease prognosis [38]. Increased expression of CCL3 in bone biopsies correlates with extensive bone disease, increased angiogenesis, and advanced stage in newly diagnosed patients with MM [39]. CCL3, secreted by MM cells, stimulates OC activity and also inhibits osteoblast formation, further contributing to the imbalance between bone resorption and bone formation [40]. MM cells also secrete CCL5, suggesting a possible role of this chemokine in the pathogenesis of MM since, like CCL3, it is a potent activator of both CCR1 and CCR5 receptors [41] expressed by stromal cells and OC precursors [35].

Several studies have evaluated the expression of CCR5 and CCR1 by MM cell lines and by cells derived from patients [34, 35, 42–45] and demonstrated that their engagement determines MM cell survival, migration, and homing to the BM. In fact, MM cells migrate in the presence of CCL5 and the extent of migration depends on the CCR5 expression levels [35, 43, 45].

Inhibition of CCR1 and CCR5 receptors by antagonists or neutralizing antibodies partially reduce osteoclastogenesis, osteolytic lesions, and MM-induced angiogenesis [34, 35, 42]. Recently, Dairaghi et al. [46] demonstrated that CCR1 blockade by the selective antagonist CCX721 reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease, likely by inhibiting the cross-talk of MM cells with OCs and OC precursors [46]. Thus the development of

CCR1 antagonists for the treatment of MM and associated osteolytic bone disease is a further therapeutic possibility.

Overall, the current observations propose two major mechanisms by which CCL3 and/or CCL5 released by tumor cells and their receptors support MM progression: the first is the ability to disrupt bone homeostasis and induce bone destruction, and the second is the bone marrow homing of MM cells [35] due to the expression of CCR5 and CCR1. Therefore, counteracting the consequences of these chemokine/chemokine receptors interactions may represent a new therapeutic option in MM.

3.2. Hodgkin Lymphoma. The microenvironment is essential for growth and survival of classical Hodgkin Lymphoma (HL) tumor cells [8] and chemokines play a primary role in its formation. They may exert a direct action on tumor cells by increasing cell survival and proliferation, recruit cells capable of sustaining the growth of tumor cells by providing a suppressive environment that suppresses cytotoxic immune responses, or redirect HL cells to advantageous microenvironmental sites within the lymphoid tissues.

cHL cells secrete cytokines/chemokines and express a variety of cytokine/chemokine receptors [8, 47] and it is now widely assumed that the clinical and histological features of cHL are primarily due to the effects of a plethora of cytokines and chemokines secreted by cHL cells such as CCL5 [48, 49], CCL17 [47], CCL22 [50], CCL28 [51], and CCL20 [39, 52] or by the surrounding cellular infiltrate. The recruitment and proliferation of nontumor cells may be also mediated by molecules produced by “normal” cells of the microenvironment, activated by tumor cells [8]. For example: cHL cells (i) do not express eotaxin but produce IL-13 and TNF- α which are capable of inducing eotaxin expression in cocultured dermal fibroblasts in a concentration leading to a specific chemotactic response of Th2 cells [53]; (ii) produce molecules capable of inducing CCL5 secretion in HL-derived fibroblasts [49]; (iii) express CD40 and its engagement by CD40L rosetting T-cells increase CCL5 secretion [49]. Together these lines of evidence suggest that the cross-talk between tumor cells and fibroblasts or the activation by surrounding CD40L+ T-cells may be involved in the influx and further proliferation of inflammatory cells typical of the HL microenvironment. Accordingly, when compared with control lymph nodes or tissues diagnosed with reactive lymphoid hyperplasia, cHL tissues display higher levels of chemokines such as CCL5 and CCL3 [47, 48]. Both chemokines are significantly higher in EBV-positive than in EBV-negative HL tissues [47], consistent with the fact that the EBV gene LMP1 is necessary to induce the expression of CCL5 in EBV-negative cell lines [54].

Both CCR5 [49] and CCL5 [48, 49] are also constitutively expressed by cHL-derived cell lines (L-428, KM-H2, L-1236, and L-540), by tumor cells from cHL lymph node tissues, and by bystander cells including lymphocytes and macrophages [49]. CCR5 receptor is functional since human recombinant CCL5 increases the clonogenic growth of cHL tumor cells. As a consequence, CCL5 secreted by the microenvironment may be a paracrine growth factor for cHL cell. Consistent




FIGURE 2: Interactions among cHL cells and the microenvironment. Proposed role of the CCL5/CCR5 axis in Hodgkin Lymphoma leading to tumor cell proliferation and microenvironment formation. CCL5 produced by cHL cells may represent an autocrine growth factor. CCL5 secreted by T cells or fibroblasts may represent a paracrine growth factor. CD40L increases CCL5 secretion by cHL cells and they induce fibroblasts to secrete CCL5. CCL5 secreted by cHL (direct recruitment) or fibroblasts activated by HL cells (indirect recruitment) may in turn recruit CD4+ T cells, T-reg cells, eosinophils, and mast cells.

with the fact that cHL cell lines expressed the CCR5 receptor and its ligand, neutralizing anti-CCL5 mAbs decrease the spontaneous clonogenic growth, suggesting that CCL5 may represent an autocrine growth factor for cHL cells. CD40 engagement [19] and cocultivation with fibroblasts from HL-involved lymph nodes (HLF) [49] increase CCL5. On the other hand, the silencing of IRF4, a transcription factor overexpressed by cHL cells and whose expression is linked to proliferation and survival [55], decreases CCL5 secretion. CCL5 secreted by cHL cells increases the migration of mast cells [48], eosinophils, CD4+ T cells [49], and likely T-reg cells [56], highlighting its involvement in the formation of the microenvironment [8].

As a consequence CCL5 and the CCR5 ligands secreted by tumor cells or by the surrounding T-cells, macrophages, or fibroblasts may support cHL progression by increasing proliferation and by recruiting cells involved in the microenvironment formation. A schematic view of the possible mechanisms (paracrine and autocrine) leading to cHL cells proliferation and microenvironment formation by CCL5 is shown in Figure 2.

4. The CCL5/CCR5 Axis in Solid Tumors

A number of solid tumor types express CCL5 and/or CCR5, but only some malignancies were widely studied, thus

providing evidence of the involvement of this pair in cancer progression and development. We briefly summarize the role of CCL5/CCR5 in melanoma and gastric, ovarian, cervical, colorectal, and prostate cancer. However, since the most extensive results were obtained in breast cancer, major emphasis is given to this malignancy.

4.1. Breast Cancer. CCL5, while being minimally expressed by normal breast epithelial duct cells, is highly expressed by breast tumor cells at primary tumor sites, regional lymph nodes, and metastatic sites, indicating that CCL5 expression is acquired in the course of malignant transformation [18] and that CCL5 plays a role in breast cancer development and/or progression. Increased positivity and expression levels of CCL5 by breast tumor cells are significantly associated with [57] disease progression, relapse, and/or metastasis, compared to patients in remission [58, 59]. In this tumor the major source of CCL5 is the tumor cells [57]; however, CCL5 is also expressed by infiltrating leukocytes and mesenchymal stem cells (MSCs) of the tumor microenvironment [15, 57, 60]. CCL5 is also present in interstitial fluids perfusing the tumor, in pleural effusions, and in serum [18].

A functional CCR5 receptor is expressed by a subpopulation of human breast cancer cell lines and displays a functional response to CCL5. In addition, oncogene transformation induces CCR5 expression, and the subpopulation of cells that express a functional CCR5 also displays increased cell migration [61] and invasiveness [62]. A microarray analysis on 2,254 human breast cancer specimens found increased expression of CCL5 and its receptor CCR5, but not CCR3, in the basal and HER-2 genetic subtypes [62]. In contrast, when a similar analysis was performed in nonneoplastic breast samples, no correlation between CCL5 and CCR5 expression levels was found, indicating that CCL5/CCR5 signaling may be preferentially activated during the development of specific breast cancer subtypes [62]. CCL5 expression is strongly associated with the progression of breast cancer, particularly the triple-negative breast cancer (TNBC), and may represent an immunotherapeutic target in the TNBC [63].

Hypoxia is a major selective factor that promotes the growth of tumors with a diminished susceptibility to radiation and chemotherapy and is associated with cancer progression, cancer metastasis, and thus poor prognosis. Hypoxia induces a strong increase of both CCL5 and CCR5 expressions by breast cancer cells [64]. Under this experimental condition CCL5 stimulates cell migration rather than cell proliferation and neutralization of CCL5 inhibits the hypoxia-induced migration of cancer cells. Similarly, overexpression of CCR5 increases cell migration, and knockdown of CCR5 attenuates hypoxia-mediated cell migration. Hypoxia-inducible factor-1 α (HIF-1 α) is involved in CCR5 and CCL5 regulation under hypoxia and HIF-1 α mRNA levels are highly correlated with CCR5 mRNA and CCL5 mRNA levels in clinical samples [64].

CCL5 also concurs with the cross-talk between breast cancer cells and MSCs: cancer cells stimulate CCL5 secretion by MSCs and osteoblasts of the tumor microenvironment and CCL5 in turn induces tumor cell migration and promotes

invasion and metastasis [15, 60]. MSCs-derived CCL5 promotes mammary tumor cell invasion and the activation of matrix metalloproteinases (MMPs), consistent with the fact that CCL5 is capable of upregulating the release of MMP-9 [65].

Tumor infiltrating cells seem bona fide prognostic and even predictive biomarkers and could be incorporated into diagnostic and therapeutic algorithms of breast cancer [18]. CCL5 supports breast malignancy by changing the equilibrium between leukocyte infiltrates in tumors, leading to dominance of cells with tumor-promoting rather than tumor-killing activities. In fact, CCL5 shifts the balance between different leukocyte cell types by increasing the presence of deleterious TAMs [10] that secrete proangiogenic factors, suppress the antitumor response [66], and inhibit the anti-tumor T-cell activities.

CCL5, together with tumor-derived colony-stimulating factors, promotes mammary tumor progression generating MDSCs in the bone marrow, helping to maintain the immunosuppressive capacity of human MDSCs [67]. CCL5 neutralization could decrease the immunosuppression activity of MDSCs, improve the efficacy against poorly immunogenic tumors, and reduce progression and metastasis.

CCL5 expression by breast tumor cells represents a valuable prognostic factor for detection of stage II breast cancer patients who are at risk for disease progression [68]. Its expression is associated with the absence of estrogen receptor, thus increasing the prognostic value of each of these two markers in patients (in the order III > II > I) at risk for progression [68]. CCL5 serum levels are elevated in breast cancer patients compared to healthy individuals [69] and tend to be higher in lymph-node-positive patients, larger tumor size, the presence of lymphovascular invasion and multifocal tumors [70].

CCL5 is also involved in drug resistance [71]. Tamoxifen resistance is a major therapeutic problem in breast cancer and a significant correlation between STAT3-RANTES autocrine signaling and acquisition of tamoxifen resistance has been reported: STAT3 and RANTES in tamoxifen-resistant MCF-7 cells regulate each other via autocrine signaling, leading to the induction of an antiapoptotic signal. This latter facilitates the maintenance of drug resistance, thus suggesting a novel strategy for the management of patients with tamoxifen-resistant tumors [71].

To conclude, based on several studies done in patients, animal model systems, and in vitro systems, the CCL5/CCR5 axis seems to have a crucial role in cancer progression and may represent an important breast cancer therapeutic target with minimal adverse impact [63].

4.2. Melanoma. Melanoma cell lines and melanoma tissues express a number of chemokines that support their growth and are implicated in tumor progression [72]. Furthermore, organ-specific patterns of melanoma metastasis correlate with the expression of specific chemokine receptors [72].

CCL5 and CCR5 are expressed by melanoma cells, primary melanomas, and cutaneous metastasis. CCL5 is higher in melanoma cells than in normal melanocytes and

is associated with a higher malignancy state and increased tumor formation [73, 74]. CCR5 is exclusively expressed in primary melanomas and some cutaneous metastases [75]. Recently, to better evaluate the significance of CCR5 expression in melanoma development, tumor growth in CCR5 knockout (CCR5^{-/-}) and wild type (CCR5^{+/+}) mice was investigated. CCR5 deficiency caused apoptotic melanoma cell death through inhibition of NF- κ B and upregulation of IL-1R α [76], thus suggesting a tumor-promoting role of CCR5. Already a previous study by Mellado et al. had shown that CCR5 plays a key role in inducing apoptotic death in tumor infiltrated lymphocytes (TIL) in a CCL5-dependent manner: CXCL12 released by melanoma cells induced the expression of CCL5 by TIL, which in turn activated their death program [77]. This activity is upregulated also by CCL3 and CCL4: they act via CCR5 to induce cytochrome-c release into the cytosol, leading to activation of caspase-9 and -3. Recently, using a mouse model of melanoma, Schlecker et al. [13] demonstrated that tumor-infiltrating monocyte-MDSCs directly attract high numbers of T-regs via CCR5 and that intratumoral injection of CCL4 or CCL5 increases tumor-infiltrating T-regs, but CCR5 deficiency led to their profound decrease. Moreover, melanoma growth is delayed in CCR5-deficient mice, likely because of a profound decrease of T-regs, emphasizing the importance of CCR5 in the control of antitumor immune responses.

The conclusion is that the CCL5/CCR5 axis seems associated with melanoma progression due to increased levels of immunosuppressive cells.

4.3. Gastric Cancer. Increased CCL5 levels are expressed by human gastric cancer cell lines characterized by a high metastatic potential [78] suggesting a tumor-promoting role of CCL5 in gastric cancer. This possibility is supported by the effects of supernatants derived from low- and high-metastatic gastric cancer cell lines on the activities of peripheral blood mononuclear cells (PBMC). Supernatants from high-metastatic gastric cancer cell lines increase CCL5 expression in PBMC, as compared to PBMC stimulated by supernatants of low-metastatic cells. In turn, tumor cells cocultured with PBMC have higher invasion properties than noncultured cells, and this process is highly inhibited by antibodies to CCL5 [79], suggesting that the cross-talk with PBMC, likely through CCL5, increases the invasion potential of tumor cells.

Several authors have then analyzed CCL5 expression in gastric cancer and found a possible correlation with the formation of metastasis. The possibility that CCL5 could serve as a predictor of metastasis was based on a study analyzing CCL5 circulating levels prior to anticancer treatment: CCL5 levels are higher in patients than in healthy controls; furthermore, the expression is higher in stage IV patients than in stages I or II-III [80] and in metastatic sites [81]. In fact, CCL5 and CCR5 are highly expressed in gastric cancer with lymph node metastasis, and CCL5 levels in the lymph nodes with cancer invasion are substantially increased, confirming the role of CCL5/CCR5 axis in metastasis formation [81].

Following infection with *Helicobacter pylori* in a gastric cancer model system CCL5 is elevated and its levels are

reduced by treatment with anti-inflammatory drugs [82]. This is in accordance with the finding that IL-2 and IFN- γ (Th1 cells) are lower and IL-10 (Th2 cells) is higher in lymph node metastasis than in cancer without metastasis, suggesting a shift toward an immunosuppressive microenvironment [82].

Expression of CCR5 by gastric tumor cells is associated with a lower survival rate [83]. Gastric cancer cells exploit CCL5, not only for their own growth, but also to assist in evasion of the host immune system [84]. CCL5 serum levels correlate with the clinical stage and treatment with CCL5 promotes tumor growth. Gastric cancer cells stimulate CD4+ T lymphocytes to secrete CCL5 and they may also induce Fas-FasL-mediated apoptosis of CD8+ T lymphocytes using CCL5 [84].

The conclusion is that the CCL5/CCR5 axis seems associated with gastric cancer progression due to increased growth and metastasis formation.

4.4. Colon Cancer. The CCL5/CCR5 axis plays also a role in colon cancer since CCL5 and its receptors are overexpressed within primary as well as liver and pulmonary metastases compared to healthy tissues [85]. CCL5 increases the in vitro growth and the migratory responses of colon cancer cells from both human and mouse origins. In addition, systemic treatment of mice with neutralizing anti-CCL5 antibodies reduced the extent of subcutaneous tumors, liver metastases, and peritoneal carcinosis. More recently, a novel mechanism of immune escape mediated by CCL5 was defined by Chang et al. [11]. Knockdown of CCL5 from CT26 mouse colon tumor cells decreases apoptosis of tumor-infiltrating CD8+ T cells and reduces tumor growth in mice. Here, CCL5 not only promotes migration of T-reg cells to tumors but also enhances the killing ability on CD8+ T cells. This augmented function is associated with the increased release of TGF- β by T-reg cells [11].

While a treatment with TAK-779, a CCR5 antagonist, only partially compromises colon progression, CCL5 neutralization renders the tumors more sensitive to a PDGFR β -directed strategy in mice. It is of note that this combination regimen offers the greatest protection against liver metastases and fully suppresses macroscopic peritoneal carcinosis. The conclusion is that CCL5/CCR5 signaling recruits T-regs which in turn eliminate CD8+ T cells, thereby defining a novel mechanism of immune escape in colorectal cancer and pointing to the potential value of CCL5 as a therapeutic target [11].

4.5. Prostate Cancer. The CCL5/CCR5 axis is involved also in prostate cancer (PCa) progression: both are expressed in human prostate cancer (PCa) cell lines, primary cultures of prostatic adenocarcinoma cells, and PCa tissues [86]. CCL5 stimulates PCa cell proliferation and invasion and both are inhibited by the CCR5 antagonist TAK-779 [87]. CCL5 increases PCa proliferation in synergy with IL-6 and it is also induced by the antibody-mediated aggregation of the prostate specific membrane antigen (PSMA) [88]. PSMA is a type-II integral membrane protein capable of activating the NF- κ B transcription factor [88], predominantly localized to the

epithelial cells of the prostate gland and whose expression increases several fold in high-grade prostate cancers and in metastatic and in androgen-insensitive prostate carcinoma [88].

Serum CCL5 levels do not differ among prostate cancer patients with or without paclitaxel resistance but the expression of the CCR1 receptor increases in paclitaxel-resistant PC3 prostate cancer cells [27]. Interaction between CCR1 and CCL5 promotes the invasion of taxane-resistant PC3 prostate cancer cells by increasing the secretion of MMP-2 and -9 via ERK and Rac activation [27] suggesting that CCR1 could be a novel therapeutic target for taxane-resistant prostate cancer.

4.6. Ovarian Cancer. CCL5 expression is detected not only in malignant ovarian biopsies, but also in normal biopsies, with minimal expression in ovarian cancer cell lines [89]. The cell types expressing CCL5 in the biopsies are not yet determined, but it is likely that infiltrating leukocytes constitute the major origin of this chemokine in ovarian tumors [89].

However, recently Long et al. [26] demonstrated that CCL5 is expressed in ovarian cancer stem cells (CSLCs) characterized by the expression of CD133 antigen that identifies a specific subpopulation of human ovarian cancer cell line and ovarian cancer tissue in which migration and invasion are particularly enhanced. In comparison to CD133-negative non-CSLCs, CCL5 and its receptors, CCR1, CCR3, and CCR5, are consistently upregulated in CD133-positive cells, and blocking of CCL5, CCR1, or CCR3 effectively inhibits the invasive capacity of CSLCs. The enhanced invasiveness is mediated through NF- κ B activation along with elevated MMP-9 secretion, suggesting that the autocrine activation of CCR1 and CCR3 by CCL5 represents one of the major mechanisms underlying the metastatic property of ovarian cancer cells [26].

Evidence supporting an association between CCL5 and ovarian carcinoma progression was also provided by a study analyzing chemokine levels in plasma of patients at different stages of disease. CCL5 levels are higher in ovarian cancer patients than in patients diagnosed with benign ovarian cysts and elevated in stages III-IV of ovarian cancer compared to stages I-II [90]. CCL5, along with CCL3 and CCL4, is present in ascitic fluids of ovarian carcinoma patients, and their levels positively correlate with the extent of T lymphocytes infiltration [91]. CCR5 and CCR1 are mainly detected in T lymphocytes and monocytes but only low expression of CCR5 is detected in the tumor cells [26, 91].

Cancer-associated fibroblasts (CAFs) are fibroblasts altered by the continuous exposure to cancer cells residing within the tumor microenvironment [92]. CAFs promote cancer cell invasion, proliferation, and metastasis by secreting cytokines and chemokines, which stimulate receptor tyrosine kinase signaling and epithelial-mesenchymal transition (EMT) programs [2].

The cultivation of ovarian cancer cells with normal fibroblasts generates CAFs possibly through the secretion of molecules that regulate the expression of miRNAs, non-coding RNA molecules that regulate gene expression at a posttranscriptional level [93]. The cross-talk between ovarian cancer cells and fibroblasts decreases *miR-31* and *miR-214*

and increases *miR-155* expression, reprogramming normal fibroblasts into tumor-promoting cancer-associated fibroblasts. CCL5 is a key target of *miR-214* and the downregulation of *miR-214* increases CCL5 production, leading to increased tumor growth [94]. Anti-CCL5 antibodies block the effect of CAFs on tumor growth and cell migration [94] and CCL5-transfected normal fibroblasts increase the invasion of ovarian cancer cells [94], suggesting that CCL5 is a candidate effector molecule in CAFs, contributing to tumor cell recruitment and growth. The conclusion is that CCL5 is a protumorigenic chemokine and a key target of *miR-214*, thus showing that microRNA perturbation in the stromal microenvironment can affect tumor growth by increasing the secretion of CCL5 by CAFs and suggesting that CCL5 is a possible therapeutic target in ovarian cancer.

However, at present several outstanding questions remain and the roles played by CCL5 and its receptors in ovarian cancer are far from being resolved. Many additional aspects should be studied in this disease since they may provide important considerations and new strategies for therapeutic intervention.

5. Possible Clinical Applications: CCL5 and CCR5 as Therapeutic Targets in Cancer

A fundamental objective in cancer therapy is to disrupt the interactions leading to tumor growth or to the formation of a protumorigenic and immunosuppressive microenvironment. Accordingly, our knowledge on the role of chemokine receptors in proliferation and invasion of malignant cells and the role of chemokines in the recruitment of tumor-promoting myeloid cells or lymphocytes could be exploited in new approaches to treatment.

5.1. Inhibition of CCR5/CCL5 Interactions. CCR5 is an essential coreceptor for HIV virus entry to host cells and has therefore become an attractive target for anti-HIV therapeutics development. A number of specific small molecule CCR5 antagonists that are being used as antiviral therapies, but are also effective in blocking CCR5 signal transduction, were identified by high-throughput screening efforts. Maraviroc and vicriviroc are CCR5 antagonists that exert potent blocking activities for chemokine function and HIV entry [87]. There are several lines of evidence suggesting possible clinical applications of CCR5 antagonists in cancer treatment. Maraviroc or vicriviroc reduces in vitro invasion of basal breast cancer cells without affecting cell proliferation or viability [95, 96]. Maraviroc, that has already been licensed by FDA for the use in humans, prevents the development of hepatocellular carcinoma [97] in a mouse model and decreases pulmonary metastasis in a preclinical mouse model of breast cancer [62, 96], suggesting that CCR5 antagonists could be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype.

The nonpeptide CCR5 antagonist TAK-779 is a small molecular weight quaternary ammonium derivative, that binds exclusively to CCR5. It inhibits HIV infection [87] but also the CCL5-induced proliferation and invasion of PCa

cells; this suggests that this antagonist may potentially be an effective inhibitor of tumor growth and progression [86].

Anibamine [98, 99] is the first natural product reported as a CCR5 antagonist and thus provides a novel structural skeleton distinct from other lead compounds that have generally been identified from high-throughput screening efforts. Anibamine produces significant inhibition of PCa and ovarian cancer cell line OVCAR-3 proliferation without any significant cytotoxicity in NIH 3T3 fibroblastic cells [99, 100], suppresses adhesion and invasion of the highly metastatic M12 PCa cell line, and decreases PCa growth in mice [98, 99]. Based on these results, anibamine and also one of its synthetic analogues are potential leads to develop novel agents against prostate and ovarian cancer. Anibamine is currently undergoing further preclinical characterization [99, 100].

5.2. Inhibition of CCL5 Secretion. Inhibition of CCL5 secretion by cancer cell or by the tumor microenvironment may represent an additional system to affect cancer progression. MSCs are recruited by developing breast tumors where they can enhance the metastatic potential of weakly tumorigenic breast cancer cells through the secretion of CCL5 [15]. Zoledronic acid significantly affects the secretion of CCL5 and interleukin 6 in MSCs [101] suggesting that the drug could contribute to antitumor activity by affecting the ability of MSCs to interact with breast cancer cells. Alternatively, chemotherapy drugs could affect both proliferation and the formation of an immunosuppressive microenvironment by decreasing the secretion of CCL5 by cancer cells, as reported for the PI3K δ -specific inhibitor GS-1101 in cHL cells [9].

5.3. Inhibition of Cross-Talk (CCL5 Secretion). Another therapeutic modality that deserves some consideration deals with the potential utilization of the cross-talk between cancer cells and cellular constituent of the microenvironment. Along this line we recently found that the EGFR-tyrosine kinase inhibitor gefitinib negatively affects EGFR activation by PC3-CM leading to decreased secretion of CCL5 by MSCs [102].

Overall, anti-CCL5 drugs could affect both tumor cell proliferation and/or the formation of an immunosuppressive microenvironment by decreasing the secretion of CCL5 by cancer cells.

A schematic view of the possible therapeutic application is shown in Figure 3.

6. Conclusions

The investigation of the roles played by CCL5/CCR5 in tumor development and metastasis is only in its infancy. While promalignancy effects are strongly implicated in MM and breast cancer, their contribution to other malignancies such as cHL, melanoma, gastric, prostate, and ovarian and colon cancer deserves further studies.

Furthermore, one has to take into account the fact that the CCL5/CCR5 axis acts in conjunction with other chemokines to affect the malignant phenotype (e.g., the CXCL12/CXCR4




FIGURE 3: CCL5 and CCR5 as therapeutic targets in cancer. Different strategies proposed to disrupt the CCL5/CCR5 axis. (a) CCL5/CCL5 interaction may be inhibited by CCR5 antagonists. (b) CCL5 secretion by tumor cells or by MSCs of the tumor microenvironment may be decreased by treatment with chemotherapeutic agents. (c) The interactions between tumor cells and MSCs, mediated by EGF/EGFR pair, leading to increased CCL5 secretion by MSCs, may be inhibited by the EGFR-tyrosine kinase inhibitor gefitinib.

pair), exemplifying the multifactorial nature of malignancies and the need to target several mediators simultaneously. Also, in considering CCL5/CCR5 as therapeutic targets, we should evaluate the effects of anti-CCL5/CCR5 treatments on the immune integrity of the host. The optimal therapeutic modalities would have to accommodate two opposing demands: the need to inhibit the detrimental involvement of CCL5 and CCR5 in specific malignant diseases protecting their potentially beneficial activities in immunity, including the anticancer immune responses.

Overall, our current knowledge leads us to suggest the CCL5/CCR5 axis as a potential therapeutic target in several cancer diseases. However, bringing this proposal into practical application requires further research to more clearly elucidate the effects of CCL5 on cancer progression and the formation of an immunosuppressive microenvironment to insure that such treatments are supported by the appropriate rationale.

Finally, as postulated by Schall and Proudfoot, [103] the right target selection, time of intervention, and, in particular, functional dose may be the key to developing successful chemokine-targeted drugs not only for inflammatory diseases but also for cancer.

Conflict of Interests

The authors declare that there is no conflict of interests.

Acknowledgment

This work is supported by Ministero della Salute, Ricerca Finalizzata FSN, I.R.C.C.S., Rome, Italy.

References

- [1] A. Mantovani, "Molecular pathways linking inflammation and cancer," *Current Molecular Medicine*, vol. 10, no. 4, pp. 369–373, 2010.
- [2] D. Hanahan and L. M. Coussens, "Accessories to the crime: functions of cells recruited to the tumor microenvironment," *Cancer Cell*, vol. 21, no. 3, pp. 309–322, 2012.
- [3] M. H. Kershaw, J. A. Westwood, and P. K. Darcy, "Gene-engineered T cells for cancer therapy," *Nature Reviews Cancer*, vol. 13, no. 8, pp. 525–541, 2013.
- [4] R. K. Jain, "Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers," *Journal of Clinical Oncology*, vol. 31, no. 17, pp. 2205–2218, 2013.

- [5] A. Zlotnik and O. Yoshie, "The chemokine superfamily revisited," *Immunity*, vol. 36, no. 5, pp. 705–716, 2012.
- [6] J. Candido and T. Hagemann, "Cancer-related inflammation," *Journal of Clinical Immunology*, vol. 33, supplement 1, pp. S79–S84, 2013.
- [7] F. R. Balkwill, "The chemokine system and cancer," *Journal of Pathology*, vol. 226, no. 2, pp. 148–157, 2012.
- [8] D. Aldinucci, A. Gloghini, A. Pinto, R. de Filippi, and A. Carbone, "The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape," *Journal of Pathology*, vol. 221, no. 3, pp. 248–263, 2010.
- [9] S. A. Meadows, F. Vega, A. Kashishian et al., "PI3K δ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma," *Blood*, vol. 119, no. 8, pp. 1897–1900, 2012.
- [10] J. Cook and T. Hagemann, "Tumour-associated macrophages and cancer," *Current Opinion in Pharmacology*, vol. 13, no. 4, pp. 595–601, 2013.
- [11] L.-Y. Chang, Y.-C. Lin, J. Mahalingam et al., "Tumor-derived chemokine CCL5 enhances TGF- β -mediated killing of CD8⁺ T cells in colon cancer by T-regulatory cells," *Cancer Research*, vol. 72, no. 5, pp. 1092–1102, 2012.
- [12] X. Yang, J. Hou, Z. Han et al., "One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment," *Cell & Bioscience*, vol. 3, no. 1, pp. 5–3, 2013.
- [13] E. Schlecker, A. Stojanovic, C. Eisen et al., "Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth," *The Journal of Immunology*, vol. 189, no. 12, pp. 5602–5611, 2012.
- [14] A. Ben-Baruch, "The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory axis of TNF α and chemokines," *Cancer Microenvironment*, vol. 5, no. 2, pp. 151–164, 2012.
- [15] A. E. Karnoub, A. B. Dash, A. P. Vo et al., "Mesenchymal stem cells within tumour stroma promote breast cancer metastasis," *Nature*, vol. 449, no. 7162, pp. 557–563, 2007.
- [16] P. Allavena, G. Germano, F. Marchesi, and A. Mantovani, "Chemokines in cancer related inflammation," *Experimental Cell Research*, vol. 317, no. 5, pp. 664–673, 2011.
- [17] M. Oppermann, "Chemokine receptor CCR5: insights into structure, function, and regulation," *Cellular Signalling*, vol. 16, no. 11, pp. 1201–1210, 2004.
- [18] G. Soria and A. Ben-Baruch, "The inflammatory chemokines CCL2 and CCL5 in breast cancer," *Cancer Letters*, vol. 267, no. 2, pp. 271–285, 2008.
- [19] D. Aldinucci, A. Gloghini, A. Pinto, A. Colombatti, and A. Carbone, "The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment," *Leukemia and Lymphoma*, vol. 53, no. 2, pp. 195–201, 2012.
- [20] M. J. Chenoweth, M. F. Mian, N. G. Barra et al., "IL-15 can signal via IL-15R α , JNK, and NF- κ B To drive RANTES production by myeloid cells," *Journal of Immunology*, vol. 188, no. 9, pp. 4149–4157, 2012.
- [21] J. Udi, J. Schuler, D. Wider et al., "Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization," *British Journal of Haematology*, vol. 161, no. 1, pp. 104–116, 2013.
- [22] V. Appay and S. L. Rowland-Jones, "RANTES: a versatile and controversial chemokine," *Trends in Immunology*, vol. 22, no. 2, pp. 83–87, 2001.
- [23] B. Roscic-Mrkic, M. Fischer, C. Leemann et al., "RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement," *Blood*, vol. 102, no. 4, pp. 1169–1177, 2003.
- [24] A. J. Ridley, M. A. Schwartz, K. Burridge et al., "Cell migration: integrating signals from front to back," *Science*, vol. 302, no. 5651, pp. 1704–1709, 2003.
- [25] C.-Y. Huang, Y.-C. Fong, C.-Y. Lee et al., "CCL5 increases lung cancer migration via PI3K, Akt and NF- κ B pathways," *Biochemical Pharmacology*, vol. 77, no. 5, pp. 794–803, 2009.
- [26] H. Long, R. Xie, T. Xiang et al., "Autocrine CCL5 signaling promotes invasion and migration of CD133⁺ ovarian cancer stem-like cells via NF- κ B-mediated MMP-9 upregulation," *Stem Cells*, vol. 30, no. 10, pp. 2309–2319, 2012.
- [27] T. Kato, Y. Fujita, K. Nakane et al., "CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling," *Cytokine*, vol. 64, no. 1, pp. 251–257, 2013.
- [28] J. E. Kim, H. S. Kim, Y. J. Shin et al., "LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression," *Experimental and Molecular Medicine*, vol. 40, no. 5, pp. 514–522, 2008.
- [29] S.-W. Wang, H.-H. Wu, S.-C. Liu et al., "CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma," *PLoS ONE*, vol. 7, no. 4, Article ID e35101, 2012.
- [30] D. Raman, T. Sobolik-Delmaire, and A. Richmond, "Chemokines in health and disease," *Experimental Cell Research*, vol. 317, no. 5, pp. 575–589, 2011.
- [31] D. F. Gao and E. N. Fish, "89: a role for CCL5 in breast cancer cell metabolism," *Cytokine*, vol. 63, no. 3, p. 264, 2013.
- [32] I. Borrello, "Can we change the disease biology of multiple myeloma?" *Leukemia Research*, vol. 36, supplement 1, pp. S3–S12, 2012.
- [33] M. Abe, K. Hiura, J. Wilde et al., "Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion," *Blood*, vol. 104, no. 8, pp. 2484–2491, 2004.
- [34] Y. Oba, J. W. Lee, L. A. Ehrlich et al., "MIP-1 α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells," *Experimental Hematology*, vol. 33, no. 3, pp. 272–278, 2005.
- [35] E. Menu, E. de Leenheer, H. de Raeve et al., "Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model," *Clinical and Experimental Metastasis*, vol. 23, no. 5-6, pp. 291–300, 2006.
- [36] G. D. Roodman and S. J. Choi, "MIP-1 alpha and myeloma bone disease," *Cancer Treatment and Research*, vol. 118, pp. 83–100, 2004.
- [37] T. Hashimoto, M. Abe, T. Oshima et al., "Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1 α and MIP-1 β correlates with lytic bone lesions in patients with multiple myeloma," *British Journal of Haematology*, vol. 125, no. 1, pp. 38–41, 2004.
- [38] E. Terpos, M. Politou, R. Szydlo, J. M. Goldman, J. F. Apperley, and A. Rahemtulla, "Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 α) correlate with the extent of bone disease and survival in patients with multiple myeloma," *British Journal of Haematology*, vol. 123, no. 1, pp. 106–109, 2003.

- [39] M. Roussou, A. Tasidou, M. A. Dimopoulos et al., "Increased expression of macrophage inflammatory protein-1 α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma," *Leukemia*, vol. 23, no. 11, pp. 2177–2181, 2009.
- [40] S. Vallet, S. Pozzi, K. Patel et al., "A novel role for CCL3 (MIP-1 α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function," *Leukemia*, vol. 25, no. 7, pp. 1174–1181, 2011.
- [41] Y. Cao, T. Luetkens, S. Kobold et al., "The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients," *Experimental Hematology*, vol. 38, no. 10, pp. 860–867, 2010.
- [42] M. Abe, K. Hiura, J. Wilde et al., "Role for macrophage inflammatory protein (MIP)-1 α and MIP-1 β in the development of osteolytic lesions in multiple myeloma," *Blood*, vol. 100, no. 6, pp. 2195–2202, 2002.
- [43] S. Lentzsch, M. Gries, M. Janz, R. Bargou, B. Dörken, and M. Y. Mapara, "Macrophage inflammatory protein 1-alpha (MIP-1 α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells," *Blood*, vol. 101, no. 9, pp. 3568–3573, 2003.
- [44] S. Vallet and K. C. Anderson, "CCR1 as a target for multiple myeloma," *Expert Opinion on Therapeutic Targets*, vol. 15, no. 9, pp. 1037–1047, 2011.
- [45] C. Möller, T. Strömberg, M. Juremalm, K. Nilsson, and G. Nilsson, "Expression and function of chemokine receptors in human multiple myeloma," *Leukemia*, vol. 17, no. 1, pp. 203–210, 2003.
- [46] D. J. Dairaghi, B. O. Oyajobi, A. Gupta et al., "CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease," *Blood*, vol. 120, no. 7, pp. 1449–1457, 2012.
- [47] E. Maggio, A. van den Berg, A. Diepstra, J. Kluiver, L. Visser, and S. Poppema, "Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues," *Annals of Oncology*, vol. 13, supplement 1, pp. 52–56, 2002.
- [48] M. Fischer, M. Juremalm, N. Olsson et al., "Expression of CCL5/RANTES by Hodgkin and reed-sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue," *International Journal of Cancer*, vol. 107, no. 2, pp. 197–201, 2003.
- [49] D. Aldinucci, D. Lorenzon, L. Cattaruzza et al., "Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions," *International Journal of Cancer*, vol. 122, no. 4, pp. 769–776, 2008.
- [50] M. Niens, L. Visser, I. M. Nolte et al., "Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22," *British Journal of Haematology*, vol. 140, no. 5, pp. 527–536, 2008.
- [51] H. Hanamoto, T. Nakayama, H. Miyazato et al., "Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells," *American Journal of Pathology*, vol. 164, no. 3, pp. 997–1006, 2004.
- [52] K. R. N. Baumforth, A. Birgersdotter, G. M. Reynolds et al., "Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells," *American Journal of Pathology*, vol. 173, no. 1, pp. 195–204, 2008.
- [53] F. Jundt, I. Anagnostopoulos, K. Bommert et al., "Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils," *Blood*, vol. 94, no. 6, pp. 2065–2071, 1999.
- [54] J. N. Uchihara, A. M. Krensky, T. Matsuda et al., "Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1," *International Journal of Cancer*, vol. 114, no. 5, pp. 747–755, 2005.
- [55] D. Aldinucci, M. Celegato, C. Borghese, A. Colombatti, and A. Carbone, "IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion," *British Journal of Haematology*, vol. 152, no. 2, pp. 182–190, 2011.
- [56] D. Aldinucci, A. Pinto, A. Gloghini, and A. Carbone, "Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond," *Blood*, vol. 115, no. 3, pp. 746–747, 2010.
- [57] G. Luboshits, S. Shina, O. Kaplan et al., "Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma," *Cancer Research*, vol. 59, no. 18, pp. 4681–4687, 1999.
- [58] Y. Niwa, H. Akamatsu, H. Niwa, H. Sumi, Y. Ozaki, and A. Abe, "Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer," *Clinical Cancer Research*, vol. 7, no. 2, pp. 285–289, 2001.
- [59] I. Bièche, F. Lerebours, S. Tozlu, M. Espie, M. Marty, and R. Lidereau, "Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature," *Clinical Cancer Research*, vol. 10, no. 20, pp. 6789–6795, 2004.
- [60] Z. Mi, S. D. Bhattacharya, V. M. Kim, H. Guo, L. J. Talbotq, and P. C. Kuo, "Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis," *Carcinogenesis*, vol. 32, no. 4, pp. 477–487, 2011.
- [61] Y. Zhang, F. Yao, X. Yao et al., "Role of CCL5 in invasion, proliferation and proportion of CD44⁺/CD24⁻ phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression," *Oncology Reports*, vol. 21, no. 4, pp. 1113–1121, 2009.
- [62] M. Velasco-Velazquez, X. Jiao, M. de la Fuente et al., "CCR5 antagonist blocks metastasis of basal breast cancer cells," *Cancer Research*, vol. 72, no. 15, pp. 3839–3850, 2012.
- [63] D. Lv, Y. Zhang, H. J. Kim, L. Zhang, and X. Ma, "CCL5 as a potential immunotherapeutic target in triple-negative breast cancer," *Cellular & Molecular Immunology*, vol. 10, no. 4, pp. 303–310, 2013.
- [64] S. Lin, S. Wan, L. Sun et al., "Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia," *Cancer Science*, vol. 103, no. 5, pp. 904–912, 2012.
- [65] M. Swamydas, K. Ricci, S. L. Rego, and D. Dreau, "Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases," *Cell Adhesion & Migration*, vol. 7, no. 3, pp. 315–324, 2013.
- [66] E. Azenshtein, G. Luboshits, S. Shina et al., "The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity," *Cancer Research*, vol. 62, no. 4, pp. 1093–1102, 2002.
- [67] Y. Zhang, D. Lv, H. J. Kim et al., "A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells," *Cell Research*, vol. 23, no. 3, pp. 394–408, 2013.
- [68] N. Yaal-Hahoshen, S. Shina, L. Leider-Trejo et al., "The chemokine CCL5 as a potential prognostic factor predicting

- disease progression in stage II breast cancer patients," *Clinical Cancer Research*, vol. 12, no. 15, pp. 4474–4480, 2006.
- [69] Z. A. Dehqanzada, C. E. Storrer, M. T. Hueman et al., "Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology," *Oncology Reports*, vol. 17, no. 3, pp. 687–694, 2007.
- [70] A. Smeets, B. Brouwers, S. Hatse et al., "Circulating CCL5 levels in patients with breast cancer: is there a correlation with lymph node metastasis?" *ISRN Immunology*, vol. 2013, Article ID 453561, 5 pages, 2013.
- [71] E. H. Yi, C. S. Lee, J. K. Lee et al., "STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells," *Molecular Cancer Research*, vol. 11, no. 1, pp. 31–42, 2013.
- [72] A. S. Payne and L. A. Cornelius, "The role of chemokines in melanoma tumor growth and metastasis," *Journal of Investigative Dermatology*, vol. 118, no. 6, pp. 915–922, 2002.
- [73] U. Mrowietz, U. Schwenk, S. Maune et al., "The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice," *British Journal of Cancer*, vol. 79, no. 7–8, pp. 1025–1031, 1999.
- [74] S. Mattei, M. P. Colombo, C. Melani, A. Silvani, G. Parmiani, and M. Herlyn, "Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes," *International Journal of Cancer*, vol. 56, no. 6, pp. 853–857, 1994.
- [75] H. Seidl, E. Richtig, H. Tilz et al., "Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma," *Human Pathology*, vol. 38, no. 5, pp. 768–780, 2007.
- [76] J. K. Song, M. H. Park, D.-Y. Choi et al., "Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF- κ B and upregulation of IL-1Ra in Melanoma model," *PLoS ONE*, vol. 7, no. 5, Article ID e33747, 2012.
- [77] M. Mellado, A. M. de Ana, M. C. Moreno, C. Martínez, and J. M. Rodríguez-Frade, "A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death," *Current Biology*, vol. 11, no. 9, pp. 691–696, 2001.
- [78] R. Fukui, H. Nishimori, F. Hata et al., "Metastases-related genes in the classification of liver and peritoneal metastasis in human gastric cancer," *Journal of Surgical Research*, vol. 129, no. 1, pp. 94–100, 2005.
- [79] K. Okita, T. Furuhashi, Y. Kimura et al., "The interplay between gastric cancer cell lines and PBMCs mediated by the CC chemokine RANTES plays an important role in tumor progression," *Journal of Experimental and Clinical Cancer Research*, vol. 24, no. 3, pp. 439–446, 2005.
- [80] H. K. Kim, K. S. Song, Y. S. Park et al., "Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor," *European Journal of Cancer*, vol. 39, no. 2, pp. 184–191, 2003.
- [81] Z. Cao, X. Xu, X. Luo et al., "Role of RANTES and its receptor in gastric cancer metastasis," *Journal of Huazhong University of Science and Technology—Medical Science*, vol. 31, no. 3, pp. 342–347, 2011.
- [82] K. B. Hahm, Y. J. Song, T. Y. Oh et al., "Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible?" *Journal of Biochemistry and Molecular Biology*, vol. 36, no. 1, pp. 82–94, 2003.
- [83] H. Sugawara, T. Ichikura, H. Tsujimoto et al., "Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer," *Journal of Surgical Oncology*, vol. 97, no. 5, pp. 445–450, 2008.
- [84] H. Sugawara, T. Ichikura, M. Kinoshita et al., "Gastric cancer cells exploit CD4⁺ cell-derived CCL5 for their growth and prevention of CD8⁺ cell-involved tumor elimination," *International Journal of Cancer*, vol. 122, no. 11, pp. 2535–2541, 2008.
- [85] B. Cambien, P. Richard-Fiardo, B. F. Karimjee et al., "CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFR β in colorectal carcinoma," *PLoS ONE*, vol. 6, no. 12, Article ID e28842, 2011.
- [86] G. G. Vaday, D. M. Peehl, P. A. Kadam, and D. M. Lawrence, "Expression of CCL5 (RANTES) and CCR5 in prostate cancer," *Prostate*, vol. 66, no. 2, pp. 124–134, 2006.
- [87] K. Maeda, D. Das, H. Nakata, and H. Mitsuya, "CCR5 inhibitors: emergence, success, and challenges," *Expert Opinion on Emerging Drugs*, vol. 17, no. 2, pp. 135–145, 2012.
- [88] M. Colombatti, S. Grasso, A. Porzia et al., "The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways," *PLoS ONE*, vol. 4, no. 2, Article ID e4608, 2009.
- [89] R. P. M. Negus, G. W. H. Stamp, J. Hadley, and F. R. Balkwill, "Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines," *American Journal of Pathology*, vol. 150, no. 5, pp. 1723–1734, 1997.
- [90] S. Tsukishiro, N. Suzumori, H. Nishikawa, A. Arakawa, and K. Suzumori, "Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder," *Gynecologic Oncology*, vol. 102, no. 3, pp. 542–545, 2006.
- [91] D. Milliken, C. Scotton, S. Raju, F. Balkwill, and J. Wilson, "Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites," *Clinical Cancer Research*, vol. 8, no. 4, pp. 1108–1114, 2002.
- [92] S. Madar, I. Goldstein, and V. Rotter, "Cancer associated fibroblasts—more than meets the eye," *Trends in Molecular Medicine*, vol. 19, no. 8, pp. 447–453, 2013.
- [93] R. Schickel, B. Boyerinas, S.-M. Park, and M. E. Peter, "MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death," *Oncogene*, vol. 27, no. 45, pp. 5959–5974, 2008.
- [94] A. K. Mitra, M. Zillhardt, Y. Hua et al., "MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer," *Cancer Discovery*, vol. 2, no. 12, pp. 1100–1108, 2012.
- [95] M. Baba, O. Nishimura, N. Kanzaki et al., "A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 10, pp. 5698–5703, 1999.
- [96] M. Velasco-Velazquez and R. G. Pestell, "The CCL5/CCR5 axis promotes metastasis in basal breast cancer," *Oncoimmunology*, vol. 2, no. 4, 2013.
- [97] L. Ochoa-Callejero, L. Perez-Martinez, S. Rubio-Mediavilla, J. A. Oteo, A. Martinez, and J. R. Blanco, "Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model," *PLoS ONE*, vol. 8, no. 1, Article ID e53992, 2013.
- [98] F. Zhang, C. K. Arnatt, K. M. Haney et al., "Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents," *European Journal of Medicinal Chemistry*, vol. 55, pp. 395–408, 2012.

- [99] X. Zhang, K. M. Haney, A. C. Richardson et al., "Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents," *Bioorganic and Medicinal Chemistry Letters*, vol. 20, no. 15, pp. 4627–4630, 2010.
- [100] Y. Zhang, C. K. Arnatt, F. Zhang, J. Wang, K. M. Haney, and X. Fang, "The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents," *Bioorganic & Medicinal Chemistry Letters*, vol. 22, no. 15, pp. 5093–5097, 2012.
- [101] M. Gallo, A. de Luca, L. Lamura, and N. Normanno, "Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer," *Annals of Oncology*, vol. 23, no. 3, pp. 597–604, 2012.
- [102] C. Borghese, L. Cattaruzza, E. Pivetta et al., "Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity," *Journal of Cellular Biochemistry*, vol. 114, no. 5, pp. 1135–1144, 2013.
- [103] T. J. Schall and A. E. I. Proudfoot, "Overcoming hurdles in developing successful drugs targeting chemokine receptors," *Nature Reviews Immunology*, vol. 11, no. 5, pp. 355–363, 2011.